Cargando…

The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Dosani, T, Carlsten, M, Maric, I, Landgren, O
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4526775/ https://www.ncbi.nlm.nih.gov/pubmed/26140429 http://dx.doi.org/10.1038/bcj.2015.49

Ejemplares similares

The cellular immune system in myelomagenesis: NK cells and T cells in the development of MM and their uses in immunotherapies
por: Dosani, T, et al.
Publicado: (2015)

ALCAM-EGFR interaction regulates myelomagenesis
por: Luo, Hongmei, et al.
Publicado: (2021)

MAF functions as a pioneer transcription factor that initiates and sustains myelomagenesis
por: Katsarou, Alexia, et al.
Publicado: (2023)

Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression
por: Mondello, Patrizia, et al.
Publicado: (2017)

Genetic Manipulation of NK Cells for Cancer Immunotherapy: Techniques and Clinical Implications
por: Carlsten, Mattias, et al.
Publicado: (2015)

Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells
por: Carlsten, Mattias, et al.
Publicado: (2019)

TGF-β induces growth suppression in multiple myeloma MM.1S cells via E2F1
por: Liu, Xialei, et al.
Publicado: (2021)

Technical advances in NK cell-based cellular immunotherapy
por: Fang, Fang, et al.
Publicado: (2019)

NK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab [Corrigendum]
Publicado: (2013)

Corrigendum to “Hypoxia Impairs NK Cell Cytotoxicity through SHP-1-Mediated Attenuation of STAT3 and ERK Signaling Pathways”
por: Teng, Rui, et al.
Publicado: (2021)

CAR-NK cells: A promising cellular immunotherapy for cancer
por: Xie, Guozhu, et al.
Publicado: (2020)

Corrigendum to “Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models”
por: Zhang, Qing, et al.
Publicado: (2019)

Corrigendum to “Dual Effects of Cellular Immunotherapy in Inhibition of Virus Replication and Prolongation of Survival in HCV-Positive Hepatocellular Carcinoma Patients”
por: Qian, Lei, et al.
Publicado: (2022)

NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy
por: Wang, Wei, et al.
Publicado: (2015)

P33. NK-92 cellular immunotherapy as an alternative to donor derived peripheral blood NK cells
por: Klingemann, H
Publicado: (2014)

Allogenic natural killer cell immunotherapy of sizeable ovarian cancer: A case report
por: Xie, Silun, et al.
Publicado: (2017)

Corrigendum: treatments for resectable esophageal cancer: from traditional systemic therapy to immunotherapy
Publicado: (2023)

LIR‐1 educates expanded human NK cells and defines a unique antitumor NK cell subset with potent antibody‐dependent cellular cytotoxicity
por: Leijonhufvud, Caroline, et al.
Publicado: (2021)

A stress-induced cellular aging model with postnatal neural stem cells
por: Dong, C-M, et al.
Publicado: (2017)

New product development with the innovative biomolecular sublingual immunotherapy formulations for the management of allergic rhinitis [Corrigendum]
Publicado: (2015)

Corrigendum: Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1
Publicado: (2021)

Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy
por: Schmitz, M, et al.
Publicado: (2007)

Adoptive immunotherapy for gastric cancer using zoledronate-activated killer cells: A prospective observational study
por: Yamaguchi, Yoshiyuki, et al.
Publicado: (2022)

CORRIGENDUM: Commentary on Pharmacometrics for Immunotherapy
por: Garrido, MJ, et al.
Publicado: (2017)

Cellular expression profiles of Epstein-Barr virus-transformed B-lymphoblastoid cell lines
por: Chaiwongkot, Arkom, et al.
Publicado: (2021)

Perturbation of gut bacteria induces a coordinated cellular immune response in the purple sea urchin larva
por: Ho, Eric Ch, et al.
Publicado: (2017)

Corrigendum to “Comprehensive Humoral and Cellular Immune Responses to SARS-CoV-2 Variants in Diverse Chinese Population”
por: Li, Jiwei, et al.
Publicado: (2022)

A Hybrid Glioma Tumor Cell Lysate Immunotherapy Vaccine Demonstrates Good Clinical Efficacy in the Rat Model [Corrigendum]
Publicado: (2022)

Cellular senescence induced by aberrant MAD2 levels impacts on paclitaxel responsiveness in vitro
por: Prencipe, M, et al.
Publicado: (2010)

The Function of NK Cells in Tumor Metastasis and NK Cell-Based Immunotherapy
por: Yu, Yanlin
Publicado: (2023)

Editorial: Molecular and Cellular Pathways in NK Cell Development
por: Sitnicka, Ewa, et al.
Publicado: (2020)

Corrigendum to “Glucose Oxidase Induces Cellular Senescence in Immortal Renal Cells through ILK by Downregulating Klotho Gene Expression”
por: Troyano-Suárez, Nuria, et al.
Publicado: (2016)

Corrigendum to “Sarcoma Immunotherapy: Past Approaches and Future Directions”
por: D'Angelo, S. P., et al.
Publicado: (2015)

Corrigendum to “Percutaneous nephrolithotomy vs. extracorporeal shockwave lithotripsy for treating a 20–30 mm single renal pelvic stone” [Arab J. Urol. 13(3) (2015) 212–216]
por: Hassan, Mohammed, et al.
Publicado: (2016)

miRNAs in NK Cell-Based Immune Responses and Cancer Immunotherapy
por: Pesce, Silvia, et al.
Publicado: (2020)

Rough operators: sphingomyelinase inhibitors spike NK cells to kill cancer
por: Carlsten, Mattias, et al.
Publicado: (2023)

Withdrawal notice to: “Pan-cancer analyses of clinical prognosis, immune infiltration, and immunotherapy efficacy for TRPV family using multi-omics data” [Heliyon 9, (2023) 16897]
por: Shen, Chong, et al.
Publicado: (2023)

Corrigendum to: Cellular events and behaviors after grafting of stratified squamous epithelial cell sheet onto a hydrated collagen gel
Publicado: (2019)

Downregulation of RNF138 inhibits cellular proliferation, migration, invasion and EMT in glioma cells via suppression of the Erk signaling pathway
por: Wu, Haibin, et al.
Publicado: (2022)

NK Cell-Based Glioblastoma Immunotherapy
por: Golán, Irene, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_p9fe9dt9s2ebqtp0373q0sviuc